Home World News Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with... World News Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 790 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Tables Turned June 23, 2020 Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant... June 18, 2021 After Chemotherapy, Selma Blair Embraces Her Buzzed “Patchy Charcoal” Hair November 8, 2019 Load more HOT NEWS Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney Female Representation at the Top of the Oncology Field Has Hit... Foodie Friday: Pumpkin EVERYTHING! Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’...
